Educational use only. Not a substitute for clinical judgment. Always verify independently.
Beta-Blocker Equivalency
Convert between metoprolol, carvedilol, bisoprolol, atenolol, propranolol, nebivolol, and labetalol with HF target-dose context.
mg/day
| Drug | Daily dose | Schedule |
|---|---|---|
| Metoprolol succinate (XL) | 100mg/day | daily |
| Metoprolol tartrate (IR) | 100mg/day | BID |
| Carvedilol | 25mg/day | BID |
| Bisoprolol | 5mg/day | daily |
| Atenolol | 50mg/day | daily |
| Propranolol | 80mg/day | TID–QID (IR) |
| Nebivolol | 5mg/day | daily |
| Labetalol | 200mg/day | BID |
Target dose for HFrEF
Guideline-directed target for Metoprolol succinate (XL): 200 mg/day (MERIT-HF target). Your input is 50% of target.
Cross-class equivalency is approximate
- Carvedilol and labetalol have α-blockade — they lower BP more than a pure β1 conversion suggests.
- Receptor selectivity (β1 vs non-selective) matters in asthma, hyperthyroidism, and migraine.
- Metoprolol succinate (XL) is once-daily; tartrate is BID — total daily dose is roughly equivalent but PK is not.
- For HFrEF, only the four trial-validated agents (carvedilol, metoprolol succinate, bisoprolol, nebivolol in HFpEF/elderly) carry mortality benefit.
References
Updated 2026-04-28Report an error